click below
click below
Normal Size Small Size show me how
WEEK 7:
Obesity 2- control of appetite:
| Question | Answer |
|---|---|
| difference between hunger and appetite | desire/need for food but appetite is desire to eat food |
| food intake affected by (2) | hunger and appetite |
| satiation | feeling of fullness that terminates meal |
| satiety | feeling of repletion that inhibits further meals |
| what controls food intake | hypothalamus |
| hypothalamus-arcuate nucleus (ARC) has role in | integration of appetite signals where region of brain is not protected by BBB so allows gut hormones to pass into brain |
| pathway explaining food intake (S7)** | |
| POMC undergoes | posttranslational modification |
| POMC undergoes posttranslational modification to generate (2) | melanocortins and AgRP |
| melanocortins | act on melanocortin receptors |
| AgRP | endogenous antagonist of melanocortin-4-receptor |
| gut distension leads to release of what cells from enteroendocrine cells (6) | cholecystokinin (CCK) glucagon-like peptide-1 (GLP-1) Oxyntomodulin peptide YY (PYY3–36) apolipoprotein A-IV enterostatin |
| leptin | Peptide hormone secreted from adipose tissue |
| role of leptin | decrease food intake leading to decreased leptin levels |
| the effects of leptin is reversed by | refeeding or insulin |
| production of leptin correlates with | amount of adipose tissue (energy stores) |
| mutations in leptin leads to | severe obesity |
| when leptin is transported into the brain what does it do (3) | inhibits NPY AgRP release activates the POMC/CART neurons switch from appetite stimulation to appetite suppression |
| what does leptin do to NPY AgRP release once in the brain | inhibits them |
| what does leptin do to POMC/CART neurons once in the brain | activates them |
| insulin is increased when | positive energy balance |
| insulin is decreased when | negative energy balance |
| insulin cross BBB through | receptor mediated process |
| insulin decrease intake and body weight through | actions on ARC |
| ghrelin produced from | GIT |
| ghrelin secreted on | anticipation of food |
| ghrelin acts centrally at | ARC or brain stem to stimulate food intake through NPY and AgRP |
| ghrelin stimulates food intake through | NPY and AgRP |
| ghrelin is responsible for | being hungry at certain times of day (stimulates hunger) |
| ghrelin levels peak when | before meal |
| what happens to ghrelin levels if individual restricts energy intake to lose weight | ghrelin levels increases |
| PYY secreted from | distal GIT dependent on nutrient intake (protein> fat or CHO) |
| PYY stimulated by (3) | CCK, gastric acid and bile |
| PYY1-36 cleaved to | PYY3-36 |
| PYY1-36 cleaved to PYY3-36 acts at | NPY Y2 receptor |
| effect of PYY | inhibits food intake possibly through vagal inputs (decreases food intake in lean and obese - no resistance) |
| PYY levels stay elevated for how long | 12 hours post meal |
| CCK (cholecystokinin) released from | duodenum and jejunum in response to FAs |
| CCK acts on | receptors on vagal nerve |
| CCK possibly crosses | BBB |
| CCK effect | inhibits food intake |
| appetite linked to reward processes in brain (3) | Opioid receptors (endorphins) Cannabinoid receptors Dopamine |
| feeding is associated with | dopamine release in dorsal striatum |
| feeding is associated with dopamine release where | dorsal striatum |
| degree of pleasure correlates with | amount of dopamine released |
| bupropion | dopamine reuptake inhibitor in weight loss |
| prescription only medicines (3) | Orlistat Liraglutide Semaglutide |
| orlistat effect | inhibits gastric and pancreatic lipase with minimal absorption having 30% inhibition of lipases at normal therapeutic doses (200kcal lost/day) |
| orlistat has to be taken when | before each main meal |
| side effects of orlistat | steatorrhea and reduced absorption of fat (therefore need to monitor fat soluble vitamin status and possible need for supplements) |
| BMI has to be | >30kg/m2 or >28kg/m2 if other risk factors eg type 2 diabetes |
| drugs should only be continued after | 12 weeks if weight loss exceeds 5% |
| treatment >12 months should only be done after | discussion potential benefits and risks with patient |
| dose orlistat | 120mg taken IMMEDIATELY before or during 1 hour after each main meal (max 360mg daily) |
| when should orlistat dose be missed | if meal contains no fat |
| OTC orlistat dose | 60mg tds for max 6 months combined with reduced fat diet, BMI >28 and review after 12 weeks where dietary approaches and physical activity should be tried |
| mysimba | combination fo naltrexone and bupropion |
| mysimba has effects on | reward pathway (similar efficacy as orlistat) |
| what does NICE think of mysimba | not recommended- cost effectiveness not clear |
| sibutramine | combined NA and 5HT uptake inhibitor |
| effect of sibutramine | appetite suppressant |
| use of sibutramine | no longer used as increased blood pressure and heart rate |
| rimonabant (acomplia) | CB1 receptor antagonist Review found that benefits do not outweigh the risks |
| Phentermine (USA | not licensed in UK as increases catecholamine levels in brain and peripheral effects (increase HR, BP, palpitation) |
| liraglutide (saxenda/victoza brand name) mode of action | Binds to, and activates, the GLP-1 receptor to increase insulin secretion, suppresses glucagon secretion, and slows gastric emptying |
| liraglutide (saxenda/victoza brand name) acts on | brains subcortical areas to increase satiety |
| how often is liraglutide (saxenda/victoza brand name) used | administered daily |
| semaglutide (wegovy/ozempic brand name) mode of action | Binds to, and activates, the GLP-1 (glucagon-like peptide-1) receptor to increase insulin secretion, suppress glucagon secretion, and slow gastric emptying |
| semaglutide (wegovy/ozempic brand name) used | administered once a week |
| compare semaglutide and liraglutide | semiglutide more effective than liraglutide as it has longer duration of action |
| semiglutide recommended as option for weight management alongside | reduced calorie diet and increased physical activity |
| tirzepatide (mounjaro) mode of action | Tirzepatide activates GIP and GLP‑1 receptors. These appetite-related signals act in the brain to increase fullness and reduce hunger and food cravings; it also slows gastric emptying, particularly early in treatment. |